Han et al. (2019) demonstrated that Ythdf1-deficient mice exhibit an elevated antigen-specific CD8+ T cell anti-tumor response because suppressing YTHDF1 in the DCs enhanced the cross-presentation of tumor antigen and the cross-priming of CD8+ T cells in vivo. However, the immunomodulatory function of YTHDF1 dysregulation in HCC cells is unclear. In the present study, IHC and immunofluorescence demonstrated that YTHDF1 overexpression significantly decreased CD3+ and CD8+ T cell infiltration in HCC. This evidence concerns the gene YTHDF1 and neoplasm.